121 related articles for article (PubMed ID: 1384969)
1. Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease.
Teicher BA; Sotomayor EA; Huang ZD
Cancer Res; 1992 Dec; 52(23):6702-4. PubMed ID: 1384969
[TBL] [Abstract][Full Text] [Related]
2. beta-cyclodextrin tetradecasulfate/tetrahydrocortisol +/- minocycline as modulators of cancer therapies in vitro and in vivo against primary and metastatic Lewis lung carcinoma.
Teicher BA; Sotomayor EA; Huang ZD; Ara G; Holden S; Khandekar V; Chen YN
Cancer Chemother Pharmacol; 1993; 33(3):229-38. PubMed ID: 8269604
[TBL] [Abstract][Full Text] [Related]
3. Response of the FSaII fibrosarcoma to antiangiogenic modulators plus cytotoxic agents.
Teicher BA; Holden SA; Ara G; Northey D
Anticancer Res; 1993; 13(6A):2101-6. PubMed ID: 7507654
[TBL] [Abstract][Full Text] [Related]
4. Comparison of several antiangiogenic regimens alone and with cytotoxic therapies in the Lewis lung carcinoma.
Teicher BA; Holden SA; Ara G; Korbut T; Menon K
Cancer Chemother Pharmacol; 1996; 38(2):169-77. PubMed ID: 8616908
[TBL] [Abstract][Full Text] [Related]
5. Potential of the aminosterol, squalamine in combination therapy in the rat 13,762 mammary carcinoma and the murine Lewis lung carcinoma.
Teicher BA; Williams JI; Takeuchi H; Ara G; Herbst RS; Buxton D
Anticancer Res; 1998; 18(4A):2567-73. PubMed ID: 9703911
[TBL] [Abstract][Full Text] [Related]
6. Chemosensitization and radiosensitization of human lung and colon cancers by antimitotic agent, ABT-751, in athymic murine xenograft models of subcutaneous tumor growth.
Jorgensen TJ; Tian H; Joseph IB; Menon K; Frost D
Cancer Chemother Pharmacol; 2007 May; 59(6):725-32. PubMed ID: 16967299
[TBL] [Abstract][Full Text] [Related]
7. Optimal scheduling of interleukin 12 and chemotherapy in the murine MB-49 bladder carcinoma and B16 melanoma.
Teicher BA; Ara G; Buxton D; Leonard J; Schaub RG
Clin Cancer Res; 1997 Sep; 3(9):1661-7. PubMed ID: 9815857
[TBL] [Abstract][Full Text] [Related]
8. Angiostatin potentiates cyclophosphamide treatment of metastatic disease.
Mauceri HJ; Seetharam S; Beckett MA; Schumm LP; Koons A; Gupta VK; Park JO; Manan A; Lee JY; Montag AG; Kufe DW; Weichselbaum RR
Cancer Chemother Pharmacol; 2002 Nov; 50(5):412-8. PubMed ID: 12439600
[TBL] [Abstract][Full Text] [Related]
9. Minocycline in combination with chemotherapy or radiation therapy in vitro and in vivo.
Sotomayor EA; Teicher BA; Schwartz GN; Holden SA; Menon K; Herman TS; Frei E
Cancer Chemother Pharmacol; 1992; 30(5):377-84. PubMed ID: 1505076
[TBL] [Abstract][Full Text] [Related]
10. The antitumor effect of postoperative treatment with genistein alone or combined with cyclophosphamide in mice bearing transplantable tumors.
Wietrzyk J; Opolski A; Madej J; Radzikowski C
Acta Pol Pharm; 2000 Nov; 57 Suppl():5-8. PubMed ID: 11293263
[TBL] [Abstract][Full Text] [Related]
11. Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents.
Kakeji Y; Teicher BA
Invest New Drugs; 1997; 15(1):39-48. PubMed ID: 9195288
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of a novel podophyllotoxin derivative (TOP-53) against lung cancer and lung metastatic cancer.
Utsugi T; Shibata J; Sugimoto Y; Aoyagi K; Wierzba K; Kobunai T; Terada T; Oh-hara T; Tsuruo T; Yamada Y
Cancer Res; 1996 Jun; 56(12):2809-14. PubMed ID: 8665518
[TBL] [Abstract][Full Text] [Related]
13. Antiangiogenic treatment (TNP-470/minocycline) increases tissue levels of anticancer drugs in mice bearing Lewis lung carcinoma.
Teicher BA; Dupuis NP; Robinson MF; Emi Y; Goff DA
Oncol Res; 1995; 7(5):237-43. PubMed ID: 8534929
[TBL] [Abstract][Full Text] [Related]
14. Marked antiangiogenic and antitumor efficacy of AG3340 in chemoresistant human non-small cell lung cancer tumors: single agent and combination chemotherapy studies.
Shalinsky DR; Brekken J; Zou H; Bloom LA; McDermott CD; Zook S; Varki NM; Appelt K
Clin Cancer Res; 1999 Jul; 5(7):1905-17. PubMed ID: 10430098
[TBL] [Abstract][Full Text] [Related]
15. Improved treatment of disseminated B16f10 melanoma in mice with anticancer drugs in combination with L-histidinol.
Warrington RC; Fang WD
Anticancer Res; 1991; 11(5):1869-74. PubMed ID: 1722659
[TBL] [Abstract][Full Text] [Related]
16. Potentiation of platinum antitumor effects in human lung tumor xenografts by the angiogenesis inhibitor squalamine: effects on tumor neovascularization.
Schiller JH; Bittner G
Clin Cancer Res; 1999 Dec; 5(12):4287-94. PubMed ID: 10632372
[TBL] [Abstract][Full Text] [Related]
17. The proteasome inhibitor PS-341 in cancer therapy.
Teicher BA; Ara G; Herbst R; Palombella VJ; Adams J
Clin Cancer Res; 1999 Sep; 5(9):2638-45. PubMed ID: 10499643
[TBL] [Abstract][Full Text] [Related]
18. A metronomic schedule of cyclophosphamide combined with PEGylated liposomal doxorubicin has a highly antitumor effect in an experimental pulmonary metastatic mouse model.
Shiraga E; Barichello JM; Ishida T; Kiwada H
Int J Pharm; 2008 Apr; 353(1-2):65-73. PubMed ID: 18155369
[TBL] [Abstract][Full Text] [Related]
19. Augmentation of antitumor activity of an antibody-interleukin 2 immunocytokine with chemotherapeutic agents.
Holden SA; Lan Y; Pardo AM; Wesolowski JS; Gillies SD
Clin Cancer Res; 2001 Sep; 7(9):2862-9. PubMed ID: 11555604
[TBL] [Abstract][Full Text] [Related]
20. Lovastatin potentiates antitumor activity and attenuates cardiotoxicity of doxorubicin in three tumor models in mice.
Feleszko W; Mlynarczuk I; Balkowiec-Iskra EZ; Czajka A; Switaj T; Stoklosa T; Giermasz A; Jakóbisiak M
Clin Cancer Res; 2000 May; 6(5):2044-52. PubMed ID: 10815931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]